„Wir müssen gemessene Werte stärker mit PRO verknüpfen”

The different benefit assessments of pembrolizumab ('Keytruda') by IQWiG and the ESMO, which Institute Director Dr Thomas Kaiser addressed in the 'Monitor Health Services Research' cover interview in issue 02/25, raises fundamental questions about the methodology and prioritisation of treatment parameters. The focus is on the weighting of relapse prevention versus toxicity - a field of tension between oncological efficacy and patient-centred safety assessment. MVF spoke about this duality with Prof. Bernhard Wörmann, MD, Medical Director of the German Society for Haematology and Medical Oncology (DGHO).